...
首页> 外文期刊>Cells tissues organs >Efficient Bone Formation in a Swine Socket Lift Model Using Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 Adsorbed in beta-Tricalcium Phosphate
【24h】

Efficient Bone Formation in a Swine Socket Lift Model Using Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 Adsorbed in beta-Tricalcium Phosphate

机译:使用大肠杆菌衍生的重组人骨形态发生蛋白2吸附在β-磷酸三钙中的猪窝举升模型中的有效骨形成

获取原文
获取原文并翻译 | 示例
           

摘要

Several preclinical studies have shown that Escherichia coli-derived bone morphogenetic protein-2 (E-BMP-2) is as effective as mammalian cell-derived bone morphogenetic protein-2 (C-BMP-2) in the treatment of bone defects. However, further investigation of the effectiveness and determination of the optimal dosage of E-BMP-2 in large animals are still necessary before its full application in humans. This study investigated the efficiency of different concentrations of E-BMP-2 adsorbed in beta-TCP for bone augmentation and osseo-integration of immediate dental implants in a swine socket lift model. Following exposure of the maxillary sinus lateral wall, a 3.4-mm (diameter) cavity was drilled and filled with 0.1 g of beta-TCP containing different doses of E-BMP-2 (0, 10, 30, or 100 mu g/site) to lift the Schneiderian membrane. A dental implant was then immediately inserted. Bone-to-implant contact (BIC) and bone density (BD) examined via histological analysis were used as parameters to assess E-BMP-2 efficiency in bone formation. The implant stability quotient (ISQ) was measured using Osstell to determine the effect of E-BMP-2/beta-TCP on implant stability. After 8 weeks, the groups that received 30 and 100 mu g of E-BMP-2 showed substantial new bone formation in the elevated space, while no bone formation was observed with beta-TCP alone. Accordingly, BIC and BD presented a dose-dependent response to in-creasing doses of E-BMP-2. However, there was no increase in implant stability with E-BMP-2 treatment. In conclusion, the E-BMP-2/beta-TCP combination was efficient in bone formation and osseointegration of dental implants in a socket lift model in mini-pigs. (C) 2015 S. Karger AG, Basel
机译:多项临床前研究表明,在骨缺损的治疗中,大肠杆菌来源的骨形态发生蛋白2(E-BMP-2)与哺乳动物细胞来源的骨形态发生蛋白2(C-BMP-2)一样有效。但是,在将E-BMP-2完全应用到人体内之前,仍然有必要进一步研究E-BMP-2在大型动物中的有效性和确定最佳剂量。这项研究调查了在猪窝举升模型中,不同浓度的E-BMP-2吸附在β-TCP中对即刻牙科植入物的骨增强和骨整合的效率。暴露上颌窦侧壁后,钻出一个3.4毫米(直径)的腔,并填充0.1 g含不同剂量E-BMP-2(0、10、30或100μg/位的β-TCP) )提起施耐德膜。然后立即插入牙科植入物。通过组织学分析检查的骨-植入物接触(BIC)和骨密度(BD)作为评估E-BMP-2骨形成效率的参数。使用Osstell测量植入物稳定性商(ISQ),以确定E-BMP-2 /β-TCP对植入物稳定性的影响。 8周后,接受30和100μgE-BMP-2的组在升高的空间中显示出明显的新骨形成,而单独使用beta-TCP则没有观察到骨形成。因此,BIC和BD对E-BMP-2剂量增加呈剂量依赖性反应。但是,用E-BMP-2处理并没有增加植入物的稳定性。总之,E-BMP-2 /β-TCP组合在微型猪的窝举模型中可有效地实现牙科植入物的骨形成和骨整合。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号